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ABSTRACT 
Nasopharyngeal carcinoma (NPC) is a common cancer in Southeast Asia, including 
Malaysia. Overall survival rate of NPC patients is poor due to late diagnosis at the advanced 
stage. Thus, definitive prognostic biomarkers and multigene prognosis assessment models 
are crucial to better manage NPC. Cyclooxygenase-2 (COX-2) was identified as a significant 
prognostic biomarker via meta-analysis in head and neck (HNC) cancer, oral squamous cell 
carcinoma (OSCC) and breast cancer. Prognostic significance of COX-2 in NPC regarding 
lymph node metastasis has been done via meta-analysis. However, prognostic significance 
of COX-2 in NPC in term of overall survival (OS) rate analysed via meta-analysis remains 
unexplored. This study aims to evaluate COX-2 expression with OS and treatment response 
via meta-analysis by referring to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist. Results show that over expression of COX-2 predicts 
worse survival rate outcome for NPC (hazard ratio greater than one) but not treatment 
response (odd ratio less than one). Hazard ratio is a time dependent statistic measure while 
odd ratio is a time independent statistic measure. Hence, evaluation of COX-2 expression in 
NPC patients is important for management and treatment of NPC. Most existing NPC 
prognosis assessment models are constructed with small sample sizes and thus less relevant 
and applicable for medical practices. This study therefore aimed to construct a multigene 
NPC prognosis assessment model by pooling results of more significant meta-analysis 
studies on prognostic biomarkers of NPC via modification of PRISMA. Through this study, 
a multigene NPC prognosis assessment model consisting of ten prognostic biomarkers, 
including COX-2 done from this study is constructed. OS of NPC patients can be determined 
computationally as pooled hazard ratios (HRs) via this model by selecting the over expressed 
biomarker(s). The model can also predict the NPC prognosis assessment risk score of the 
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patient too. Through this model, patients can estimate the overall survival rate time 
effectively. To provide understanding and explanation to the multigene NPC prognosis 
assessment model generated computationally, pathways and interactions involved by all the 
prognostic biomarkers are studied to determine the physiological interactions among all the 
prognostic biomarkers incorporated. The information on the pathways and interactions are 
extracted from the literature and summarized as a molecular pathway network. The pathway 
network model explains the possible complex interplay among different prognostic 
biomarkers in the oncogenesis of NPC.  
 
Keywords: Nasopharyngeal carcinoma, meta-analysis, cyclooxygenase-2, multigene NPC 
prognosis assessment model, NPC pathway network model.  
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Meta-analisis Mengenai Ekspresi Gen Faktor Ramalan dan Penjanaan Model 
Penilaian Prognosis Pelbagai Gen dalam Karsinoma Nasofarinks  
 
ABSTRAK 
 
Karsinoma nasofarinks (NPC) ialah sejenis kanser yang lazim di Asia Tenggara, termasuk 
Malaysia. Kadar kelangsungan hidup pada pesakit NPC adalah rendah disebabkan oleh 
diagnosis lambat pada peringkat akhir. Oleh itu, faktor ramalan NPC yang muktamad dan 
modal penilaian prognosis pelbagai gen adalah penting untuk mengendali NPC dengan 
lebih baik. Cyclooxygenase-2 (COX-2) dikenali sebagai faktor ramalan yang penting 
melalui meta-analisis bagi kanser kepala dan leher, karsinoma sel skuamosa mulut dan 
kanser dada. Kepentingan COX-2 dalam prognosis NPC mengenai metastasis nodus limfa 
telah ditentukan melalui meta-analisis. Walaubagaimanapun, fungsi COX-2 sebagai faktor 
ramalan bagi menentukan kelangsungan hidup pada pesakit NPC belum lagi dikaji melalui 
meta-analisis. Matlamat kajian ini adalah untuk menilai hubungan antara ekspresi COX-2 
dengan kadar kelangsungan hidup dan tindak balas rawatan melalui meta-analisis dengan 
rujukan ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)’. 
Keputusan menunjukkan bahawa ekspresi COX-2 yang tinggi menjangkakan kadar 
kelangsungan hidup yang rendah (nisbah bahaya melebihi satu) tetapi tidak berkaitan 
dengan tindak balas rawatan (nisbah ganjil kurang daripada satu). Nisbah bahaya 
merupakan pengiraan statistik bergantung pada masa sementara nisbah ganjil merupakan 
pengiraan statistik yang tidak bergantung pada masa. Jadi, kajian untuk menilai ekspresi 
COX-2 adalah penting untuk pengurusan dan rawatan NPC yang lebih cekap. Kebanyakan 
model penilaian prognosis NPC yang sedang ada dijana dengan saiz sampel yang kecil dan 
menyebabkan model tersebut kurang berkaitan dan berguna dalam bidang perubatan. Oleh 
itu, kajian tersebut bertujuan untuk menjana model penilaian prognosis NPC pelbagai gen 
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yang berkomputasi dengan mengumpulkan keputusan meta-analisa mengenai faktor 
ramalan NPC yang lebih bermakna melalui pengubahsuaian PRISMA. Dengan kaedah 
tersebut, model penilaian prognosis NPC pelbagai gen yang terdiri daripada sepuluh faktor 
ramalan, termasuk COX-2 yang dikaji dalam kajian ini telah dijana. Kadar kelangsungan 
hidup bagi pesakit NPC dapat ditentukan secara berkomputasi sebagai nisbah bahaya 
keseluruhan (HRs) melalui model ini dengan memilih faktor ramalan yang diekspres lebih. 
Model tersebut juga dapat meramalkan angka risiko bagi penilaian prognosis NPC. Dengan 
menggunakan model ini, pesakit NPC dapat menjangka kadar hidup keseluruhan dalam 
masa yang singkat. Bagi memberikan pemahaman dan penjelasan mengenai model 
penilaian prognosis NPC pelbagai gen tersebut yang telah dijana secara berkomputasi, 
laluan dan interaksi antara faktor ramalan yang terlibat telah dikaji dan interaksi fisiologi 
telah dijelaskan. Maklumat mengenai laluan dan interaksi telah dikumpulkan dari kajian 
literatur dan diringkaskan dalam satu model rangkaian laluan NPC. Rangkaian tersebut 
menjelaskan interaksi kompleks antara faktor ramalan dalam onkogenesis NPC.  
 
Kata kunci: Karsinoma nasofarinks, meta-analisis, cyclooxygenase-2, model penilaian  
 NPC pelbagai gen, model rangkaian laluan NPC. 
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CHAPTER 1 
INTRODUCTION 
 
Nasopharyngeal carcinoma (NPC) is the formation of malignancy in the tissue of the upper 
section of pharynx behind the nose (He et al., 2016), more precisely detected at the fossa of 
Rosenmüller (Lee, Laufer, Ove, Foote & Bonner, 2012). NPC is rare in the Western 
hemisphere but widely distributed in Southeast Asia countries and in China (Chang & Adami, 
2006). In Penisular Malaysia, NPC was utmost by the Chinese, followed by the Malays and 
the Indians (Prasad & Rampal, 1992). In Sarawak, the Bidayuh indigenous group showed 
the highest incident rate with age-adjusted rate (ASR) of 31.5, which was 50% higher than 
that in Hong Kong (Devi, Pisani, Tang & Parkin, 2004). Throughout Malaysia, it is reporting 
around 4000 new cases every year (Azizah, Nor-Saleha, Noor-Hashimah, Asmah & Mastulu, 
2015). The concurrent chemoradiotherapy (CCRT) with or without neoadjuvant/adjuvant 
cisplatin-based chemotherapy are the current improved standard treatment protocol 
administrated to locally advanced NPC patients (Fendri et al., 2009; Wu et al., 2014). The 
major causes of death among NPC patient are due to local recurrence and distant metastasis, 
because a large number of patients reached advanced stage and/or metastasis at the time of 
diagnosis (You et al., 2016). Thus, prognosis is important to better increase the survival rate 
of NPC patients.  
 
A number prognostic biomarkers such as excision repair cross-complementation group 1 
(ERCC1) (Yang et al., 2019), latent membrane protein 1 (LMP1) (Chen et al., 2015), 
vascular endothelial growth factor (VEGF) (Wang et al., 2018), epidermal growth factor 
receptor (EGFR) (Sun et al., 2013), C-reactive protein (CRP) (Fang, Xu, Wu, Zhang, Li et 
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al., 2017), hypoxia-inducible factor-1 alpha (HIF-1α) (Xie et al., 2018), lactate 
dehydrogenase (LDH) (Zhai, Gu, Zhai, Wang & Zhang, 2017), lysyl oxidase (LOX) (Zhang, 
Wu, Ye & Xue, 2018) and matrix metalloproteinase 9 (MMP9) (Liao, Huang, Zhu, Li, 
Huang & He, 2016) were identified as significant prognostic indicators to determine overall 
survival (OS) of NPC patients. Comprehensive studies on these biomarkers through meta-
analysis have been carried out to draw a more definitive conclusion for the above biomarkers 
too. Over expression of cyclooxygenase-2 (COX-2) was frequently identified as a prognostic 
biomarker in different cancers such as breast cancer (Jana et al., 2014), colorectal cancer 
(Peng, Zhou, Wang, Mou & Zhao, 2013) and pancreatic cancer (Juuti, Louhimo, Nordling, 
Ristimaki & Haglund, 2006). Studies of COX-2 as prognostic biomarker in NPC have also 
been done (Pan et al., 2008; Loong et al., 2009). However, the sample sizes of these studies 
are often small (n=35 and n=58) and the results are conflicting. Even though meta-analysis 
of COX-2 in NPC regarding lymph node metastasis has been carried out (Yang et al., 2017), 
a more conclusive meta-analysis of COX-2 in NPC as prognostic biomarker regarding 
survival outcome was not done before this. Thus, this study aims to determine the prognostic 
significance of COX-2 in NPC in term of survival outcome using the approach of meta-
analysis.  
 
There are a numbers of existing NPC prognosis assessment models such as prognostic 
nomogram integrating clinical characteristic and hematological/inflammatory biomarkers 
(Li et al., 2016; Li et al., 2018). Prognostic models to determine death and distant metastasis, 
disease progression and survival in non-endemic area of China were also reported (Zhang et 
al., 2013; Zang et al., 2016; Zhao et al., 2019).  However, the sample sizes involved in the 
construction of all of these models were often relatively small. For example, study done by 
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Zhao and colleagues contained sample size of n=103 only. The patients involved in each of 
the studies were solely from a particular area and thus, these models only represented and 
reflected the response on the isolated location of studies. The usage of these models was 
therefore restricted as these models possessed little/no medical uses in other regions. 
Additionally, these models focused on clinical characteristic and had little emphasis on the 
functional genetic prognostic biomarkers. Thus, this study also aims to develop a multigene 
NPC prognosis assessment model focusing on functional genetic biomarkers by pooling 
different individual NPC prognostic meta-analysis studies computationally via modification 
of meta-analysis approach.  
 
Meta-analysis is employed in this study as it provides a more significant and precise result 
compared to single individual studies. Meta-analysis is a systematic, formal, and quantitative 
approach and study design used to identify, combine and synthesis the outcomes of previous 
relevant research. This approach is useful to draw conclusions about a body of studies 
(Haidich, 2010). The current approach used to conduct meta-analysis is by referring to 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher, 
Liberati, Tetzlaff, Altman & The PRISMA Group, 2009) (refer to Appendix A, page 157-
159). By using this method, conflicting results of different individual studies on COX-2 in 
NPC regarding the OS are pooled and analysed under the same platform to reflect a more 
significant and relevant output. By modifying PRISMA, different meta-analysis studies 
focusing on different prognostic factors in NPC are grouped into one platform. This is to 
integrate isolated aspects of different studies into a more dynamic system and this allows the 
generation of multigene NPC prognosis assessment model that is based on various functional 
genetic data. Instead of pooling individual studies that focus on the prognostic significance 
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of single biomarkers in NPC, pooling of meta-analysis studies of different prognostic 
biomarkers is therefore more significant and powerful. To our knowledge, this is the first 
time where modification of PRISMA is applied to generate multigene NPC prognosis 
assessment model containing different functional genetic biomarkers.  
 
To further understand and explain the multigene NPC prognosis assessment model designed 
computationally based on data deposited in the databases, a molecular pathway network 
among the different biomarkers is generated to postulate the physiological interactions 
among the different biomarkers. This network can clearly display the connections between 
the different biomarkers in the process of NPC carcinogenesis and hence, explain the 
complex and dynamic interactions of the pooled biomarkers in the multigene NPC prognosis 
assessment model.  
 
Herein, the objectives of this project are: 
i. To determine the prognostic significance of COX-2 in NPC in term of OS 
reflected by hazard ratios (HRs) via meta-analysis. 
ii. To generate multigene NPC prognosis assessment model focusing on functional 
genetic biomarkers by pooling different individual NPC prognostic meta-
analysis studies via modification of meta-analysis approach. 
iii. To explain the multigene NPC prognosis assessment model by generating a 
molecular pathway network among the different biomarkers. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Nasopharyngeal Carcinoma (NPC) 
2.1.1 Anatomical position of NPC  
Nasopharyngeal carcinoma (NPC) is characterized by the malignancy in the tissue of the 
upper section of pharynx behind the nose (He et al., 2016). NPC is a non-lymphomatous 
squamous cell carcinoma that particularly occurs in the mucosa epithelial lateral cell lining 
(including squamous, ciliated pseudostratified columnar and transitional epithelium) (Hong 
& Kuo, 2003) and the minor salivary glands of the nasopharynx (Sham et al., 1990; Effert 
et al., 1992; Zong, 2001; Lang, Gao, Guo, Zhao & Zhang, 2014; You et al., 2016). Refer to 
Figure 2.1, the precise and common site of tumour growth of NPC is the fossa of 
Rosenmüller, the posteromedial to the medial crura of the Eustachian tube, formed by the 
intersection of superior and posterior walls of nasopharynx (Sham et al., 1990; Jeyakumar, 
Brickman & Doerr, 2006; Lee et al., 2012).  
 
 
2.1.2 Histopatholgy of NPC  
According to World Health Organisation (WHO), NPC is histologically subclassified into 
three subtypes, namely the keratinizing differentiated squamous cell carcinoma (WHO I or 
Type I), nonkeratinizing carcinoma which can be sub-divided into nonkeratinizing 
differentiated (WHO II or Type II/IIa) and nonkeratinizing undifferentiated carcinoma 
(WHO III or Type III/IIb) and basaloid squamous cell carcinoma (Shanmugarantnam & 
Sobin, 1993; Barnes, Eveson, Reichart & Sidransky, 2005). Nonkeratinizing 
